[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594534":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":23,"locations":33,"responsibleParty":82,"collaborators":18,"id":84,"slug":18,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":85,"sex":90,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":18,"studyType":96,"phases":97,"briefSummary":99,"conditions":100,"keywords":104,"overallStatus":36,"whyStopped":18,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"University Hospital, Bordeaux","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Implantation of an ICD","EXPERIMENTAL","Patients implanted with an ICD",[13],"Device: Implantation of an ICD",{"label":15,"type":16,"description":17,"interventionNames":18},"Clinical follow-up","NO_INTERVENTION","Patients not implanted with an ICD",null,[20],{"type":21,"name":9,"description":9,"armGroupLabels":22,"otherNames":18},"DEVICE",[9],[24,29],{"name":25,"role":26,"phone":27,"phoneExt":18,"email":28},"Sylvain PLOUX, MD","CONTACT","+33(0)5 57 65 64 71","sylvain.ploux@chu-bordeaux.fr",{"name":30,"role":26,"phone":31,"phoneExt":18,"email":32},"Mélissa LABEQUE","+33(0)5 57 62 31 32","melissa.lavevre@chu-bordeaux.fr",[34,54,67],{"facility":35,"status":36,"city":37,"state":18,"zip":38,"country":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"CHU de Clermont-Ferrand","RECRUITING","Clermont-Ferrand","63000","France",{"type":41,"coordinates":42},"Point",[43,44],3.08682,45.77969,{"lat":44,"lon":43},[47,51],{"name":48,"role":26,"phone":49,"phoneExt":18,"email":50},"Grégoire MASSOULLIE, MD","+33(0)4 73 75 14 10","gmassoullie@chuclermontferrand.fr",{"name":52,"role":53,"phone":18,"phoneExt":18,"email":18},"Grégoire MASSOULLIE","PRINCIPAL_INVESTIGATOR",{"facility":55,"status":36,"city":56,"state":18,"zip":57,"country":39,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"CHU de Bordeaux - Hôpital Cardiologique du Haut-Lévêque","Pessac","33604",{"type":41,"coordinates":59},[60,61],-0.6324,44.80565,{"lat":61,"lon":60},[64,65],{"name":30,"role":26,"phone":31,"phoneExt":18,"email":32},{"name":66,"role":53,"phone":18,"phoneExt":18,"email":18},"Sylvain PLOUX",{"facility":68,"status":36,"city":69,"state":18,"zip":70,"country":39,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"CHU de Saint-Etienne","Saint-Etienne","42270",{"type":41,"coordinates":72},[73,74],4.39,45.43389,{"lat":74,"lon":73},[77,81],{"name":78,"role":26,"phone":79,"phoneExt":18,"email":80},"Karim BENALI, MD","+33(0)4 77 82 83 40","karim.benali@chu-stetienne.fr",{"name":78,"role":53,"phone":18,"phoneExt":18,"email":18},{"type":83,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100594534",false,"NCT07020702","ElectroPhySiological Characterization Of the Arrhythmia Substrate for Sudden Cardiac Death PrEdiction","EP-SCOPE","Inclusion Criteria:\n\n* Patient with cardiomyopathy with 35%\\\u003CLVEF\\\u003C50% and at least one risk factor\n* Patients with cardiomyopathy with LVEF≤35% and an indication for cardiac resynchronisation\n\nExclusion Criteria:\n\n* Patients who are minors or aged 80 or over\n* Patients with unstable coronary artery disease\n* Myocardial infarction less than 40 days old\n* Coronary revascularisation \\\u003C90 days\n* Patients with intracardiac thrombus\n* Patients with a mechanical heart valve\n* Patient implanted with an automatic defibrillator\n* Patient life expectancy \\\u003C1 year\n* Pregnant or breast-feeding women\n* Anti-arrhythmic drugs other than beta-blockers and amiodarone","ALL","18 Years","80 Years",{"count":94,"type":95},210,"ESTIMATED","INTERVENTIONAL",[98],"NA","EP-SCOPE is a prospective, multicentric, non-randomized pilot study that aims to estimate the risk of life-threatening ventricular arrhythmia through use of advanced electrophysiological studies in patients with ischemic or non-ischemic cardiomyopathy with left ventricular ejection fraction (LVEF) \\\u003C50% and risk factors of ventricular arrhythmia, otherwise not considered for implantation of an implantable cardioverter defibrillator (ICD).\n\nThe objective is to assess the effectiveness of a risk stratification strategy based on detailed electrophysiological exploration of the left ventricle and programmed ventricular stimulation.",[101,102,103],"Ventricular Arrhythmia","Cardiomyopathies","Left Ventricular Ejection Fraction Less Then or Equal to 50percent",[105,106,107],"cardiomyopathies","sudden death","Myocardial Infarction","2025-07-07",{"date":110,"type":111},"2025-07-10","ACTUAL",{"date":113,"type":111},"2023-06-12",{"date":115,"type":95},"2030-09-12",{"name":5,"class":6},3]